Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 4/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.36 |
| ▸ | WNT3A | P56704 | 3/20 | 0.35 |
| ▸ | RPS6KA2 | Q15349 | 2/20 | 0.35 |
| ▸ | SMO | Q99835 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16775921 | 0.90 | FGFR4 (0.37) | FGFR4ABL1RPS6KA2SMOHTR2A | |
| SCHEMBL16776229 | 0.89 | CYP11B2 (0.37) | FGFR4ABL1MAPK1WNT3ARPS6KA2 | |
| SCHEMBL16776016 | 0.86 | WNT3A (0.40) | ABL1MAPK1WNT3A | |
| SCHEMBL19365738 | 0.85 | FGFR4 (0.37) | FGFR4ABL1WNT3ASMOHTR2A | |
| SCHEMBL16776013 | 0.84 | FGFR4 (0.44) | FGFR4MAPK1WNT3ARPS6KA2 | |
| SCHEMBL16776211 | 0.80 | RPS6KA3 (0.43) | ABL1MAPK1WNT3ARPS6KA2 | |
| SCHEMBL16776226 | 0.80 | HTR2C (0.45) | ABL1HTR2AHTR2CHTR2B | |
| SCHEMBL16776136 | 0.80 | FAAH (0.41) | FGFR4MAPK1RPS6KA2 | |
| SCHEMBL16776424 | 0.80 | DYRK1A (0.40) | ABL1MAPK1 | |
| SCHEMBL16776102 | 0.80 | FGFR4 (0.48) | FGFR4MAPK1RPS6KA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | FGFR4 1754/4885ABL1 4089/4885MAPK1 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.